Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

A randomised controlled trial of TRANSrectal biopsy versus Local Anaesthetic Transperineal biopsy Evaluation (TRANSLATE) of potential clinically significant prostate cancer

  • Cancer HTA and economic evaluations

TRANSLATE is a UK‑wide, multi‑centre randomised clinical trial designed to determine whether local anaesthetic transperineal prostate (LATP) biopsy improves the detection of clinically significant prostate cancer (csPCa)—defined as International Society of Urological Pathology (ISUP) Grade Group ≥2 disease (any Gleason pattern 4)—compared with transrectal ultrasound‑guided prostate biopsy (TRUS) in biopsy‑naïve men. A secondary objective is to determine the cost‑effectiveness of LATP compared with TRUS.

Funder: National Institute for Health and Care Research Health Technology Assessment Programme

Chief Investigator (clinical)

Richard Bryant, Professor of Urology and Academic Director of NDS SITU

Professor Richard Bryant

University of Oxford
Alastair Lamb, Nuffield Department of Surgery, University of Oxford.

Alastair Lamb

University of Oxford

Selected publications